scholarly journals Evaluation of efficacy of anti-IgE monoclonal antibody treatment not only in severe allergic asthma

2016 ◽  
Vol 30 (4) ◽  
pp. 14-18 ◽  
Author(s):  
Jaromír Bystroň ◽  
Beata Hutyrová
Keyword(s):  
Monoclonal Antibody ◽  
Allergic Asthma ◽  
Antibody Treatment ◽  
Monoclonal Antibody Treatment ◽  
Severe Allergic Asthma

THE EFFECT OF IDARUBICIN MONOCLONAL ANTIBODY TREATMENT ON FIRST-SET REJECTION OF MURINE SKIN ALLOGRAFTS

1989 ◽  
Vol 48 (1) ◽  
pp. 77-79 ◽  
Author(s):  
M. J. SMYTH ◽  
I. F. C. MCKENZIE ◽  
G. A. PIETERSZ
Keyword(s):  
Monoclonal Antibody ◽  
Antibody Treatment ◽  
Skin Allografts ◽  
Monoclonal Antibody Treatment

scholarly journals Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment

Healthcare ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 990
Author(s):  
Herman Morchel ◽  
David Clark ◽  
Leighanne Buenvenida ◽  
Chinwe Ogedegbe
Keyword(s):  
Emergency Department ◽  
Monoclonal Antibody ◽  
Patient Care ◽  
Emergency Care ◽  
Environmental Changes ◽  
Physical Space ◽  
Antibody Treatment ◽  
Monoclonal Antibody Treatment ◽  
Mobile Satellite ◽  
Novel Coronavirus

The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexible strategies to continue to deliver efficient emergency care while maintaining appropriate physical distancing between suspect and non-suspect COVID-19 patients. The engagement of a unique rapidly deployable Mobile Satellite Emergency Department (MSED) with scalable capability from prompt care to resuscitation level allowed the emergency care team to optimize patient care and throughput. The MSED was strategically located adjacent to the ambulance entrance. While initially deployed to increase Emergency Department surge capacity, the MSED was repurposed to cohort and treat COVID patients with the monoclonal antibody, Bamlanivimab, who were expected to be discharged after treatment. This allowed for more efficient use of Emergency Department resources, including physical space and staffing.

Acute Phase Response During Monoclonal Antibody Treatment — Relationship to Antimonoclonal Sensitization

1991 ◽  
pp. 495-497
Author(s):  
G. J. Zlabinger ◽  
O. Traindl ◽  
E. Pohanka ◽  
W. Woloszczuk ◽  
R. Klauser ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Acute Phase ◽  
Acute Phase Response ◽  
Phase Response ◽  
Antibody Treatment ◽  
Treatment Relationship ◽  
Monoclonal Antibody Treatment

scholarly journals Post-SARS-CoV-2 monoclonal antibody treatment hospitalizations as a sentinel for emergence of viral variants in New York City

2021 ◽  
Author(s):  
Kelsie Cowman ◽  
Yi Guo ◽  
Liise-anne Pirofski ◽  
David Wong ◽  
Hongkai Bao ◽  
...  
Keyword(s):  
New York ◽  
Monoclonal Antibody ◽  
New York City ◽  
York City ◽  
Human Services ◽  
Antibody Treatment ◽  
Health And Human Services ◽  
Department Of Health ◽  
Monoclonal Antibody Treatment ◽  
The U.S

Abstract We partnered with the U.S. Department of Health and Human Services to treat high-risk, non-admitted COVID-19 patients with bamlanivimab in the Bronx, NY per Emergency Use Authorization criteria. Increasing post-treatment hospitalizations were observed monthly between December 2020-March 2021 in parallel to the emergence of SARS-CoV-2 variants in New York City.

scholarly journals The CD154/CD40 Interaction Required for Retrovirus-Induced Murine Immunodeficiency Syndrome Is Not Mediated by Upregulation of the CD80/CD86 Costimulatory Molecules

2002 ◽  
Vol 76 (24) ◽  
pp. 13106-13110 ◽  
Author(s):  
Kathy A. Green ◽  
W. James Cook ◽  
Arlene H. Sharpe ◽  
William R. Green
Keyword(s):  
Monoclonal Antibody ◽  
B Cells ◽  
Molecular Interactions ◽  
T And B Cells ◽  
Antibody Treatment ◽  
Monoclonal Antibody Treatment ◽  
Murine Aids ◽  
Cd40 Expression ◽  
Immunodeficiency Syndrome

ABSTRACT C57BL/6 (B6) mice infected with LP-BM5 retroviruses develop disease, including an immunodeficiency similar to AIDS. This disease, murine AIDS (MAIDS), is inhibited by in vivo anti-CD154 monoclonal antibody treatment. The similar levels of insusceptibility of CD40−/− and CD154−/− B6 mice indicate that CD154/CD40 molecular interactions are required for MAIDS. CD4+ T and B cells, respectively, provide the CD154 and CD40 expression needed for MAIDS induction. Here, the required CD154/CD40 interaction is shown to be independent of CD80 and CD86 expression: CD80/CD86−/− B6 mice develop MAIDS after LP-BM5 infection.

Sign in / Sign up

Export Citation Format

Share Document